Background
SCLC, tumor, hypoxia, recurrent/extensive stage SCLC
TUMOR, SCLC, ADVERSE EVENTS, HYPOXIA, DNA DAMAGE, REGRESSION
In recent years, people have made large efforts in improving the existing maintenance treatment strategies for ES-SCLC patients after the standard first-line chemotherapy. The poor prognosis and no preferable options may be largely related to chemotherapy drug resistance. Non-activating mutations of Recently, targeting DNA damage repair therapy including PARP inhibitors have shown therapeutic efficacy in SCLC and is considered to be a new potential treatment strategy for SCLC [Preclinical studies showed that tumor vascular regression and tissue hypoxia caused by anti-angiogenic therapy increase the sensitivity of tumor cells to PARP inhibitors, suggesting a synergistic anti-tumor effect of PARP inhibiting and anti-angiogenic therapy [Anlotinib is also a pan-inhibitor of VEGFR, which also inhibits The combination of anlotinib and fluzoparib may theoretically decrease the metabolism of fluzoparib, increase its concentration in the blood and area in the drug curve. Therefore, fluzoparib dose should be reduced appropriately. Combination of anlotinib and fluzoparib would not make adverse events and not increase the incidence of ≥ grade 3 adverse events. In theory, it is feasible in combination of the anlotinib and fluzoparib.The study protocol and informed consent of participant were discussed and approved by the Fujian Provincial Hospital Ethics Committee to fully protect the rights of participants, and the aim of the protocol is to explore the efficacy and safety of fluzoparib combined with anlotinib in the second-line treatment of patients with recurrent/extensive stage SCLC.